Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProxiMMity-1: Subcutaneous Pavurutamab in RRMM
NCT04998747Phase 1Withdrawn
- Sponsor
- Amgen
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of pavurutamab in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicities at 28 days, Treatment-Emergent Adverse Events at 9 months and 4 more. Planned start Aug 2023; status: withdrawn.
02
Drugs
pavurutamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04998747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998747.